Related Experiment Video
Updated: Aug 8, 2026
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
The human insulin analogue insulin lispro
1Department of Medicine, Helsinki University Central Hospital, Finland. veikko.koivisto@hyks.mailnet.fi
Annals of Medicine
|July 24, 1998
Summary
Insulin lispro, a modified human insulin, offers faster action and improved glucose control for diabetes management. Clinical trials show reduced hypoglycemia and better patient preference compared to traditional insulin.
Area of Science:
- Endocrinology
- Pharmacology
- Biochemistry
Background:
- Human insulin's self-association affects its pharmacokinetic profile.
- Modified insulin analogues aim to improve therapeutic outcomes.
Purpose of the Study:
- To evaluate the pharmacokinetic and clinical profile of insulin lispro.
- To compare insulin lispro with human insulin for mealtime glucose control.
Main Methods:
- Insulin lispro's amino acid sequence (lysine at B28, proline at B29) alters self-association.
- Clinical trials assessed postprandial glucose, hypoglycemia rates, and patient preference.
Main Results:
- Insulin lispro exhibits faster onset, higher peak, and shorter duration of action than human insulin.
- Clinical trials demonstrated smaller postprandial glucose spikes, lower hypoglycemia rates (especially nocturnal), and improved patient satisfaction.
- Long-term glycemic control (HbA1c) improved with insulin lispro when combined with appropriate basal insulin therapy.
Conclusions:
- Insulin lispro offers a more precise mealtime insulin profile, enhancing diabetes management.
- It represents an advancement for patients on basal-bolus insulin regimens, including those with insulin resistance.
Related Concept Videos
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...